| Pia Lippincott, MD | |
|
1600 Cloister Dr, Lancaster, PA 17601-2390 | |
| (717) 519-0793 | |
| Not Available |
| Full Name | Pia Lippincott |
|---|---|
| Gender | Female |
| Speciality | Critical Care (intensivists) |
| Experience | 19 Years |
| Location | 1600 Cloister Dr, Lancaster, Pennsylvania |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417179011 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MT185661 (Pennsylvania) | Secondary |
| 207LP2900X | Anesthesiology - Pain Medicine | MD436721 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Paris Regional Medical Center | Paris, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Regional Anesthesia Medical Group Pa | 8325328628 | 16 |
News Archive
The 2011 MAK and BAT Values List compiled by the Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area, a Senate Commission of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), recommends reducing the general threshold limit value for dust for the alveolar fraction in light of recent studies and classifies such dusts as carcinogenic when these thresholds are exceeded.
Covaris, Inc. introduced the truXTRAC™ High Throughput FFPE DNA Extraction & Purification Kit at the 2014 Advances in Genome Biology and Technology (AGBT) meeting held in Marco Island, Florida.
Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, non-invasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments.
Rather than testing for individual marker genes or proteins, researchers at the University of California, San Diego (UC San Diego) and the Moores UCSD Cancer Center have evidence that groups, or networks, of interactive genes may be more reliable in determining the likelihood that a form of leukemia is fast-moving or slow-growing.
› Verified 7 days ago
| Entity Name | Prmc Er Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366764052 PECOS PAC ID: 6709917529 Enrollment ID: O20100623000267 |
News Archive
The 2011 MAK and BAT Values List compiled by the Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area, a Senate Commission of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), recommends reducing the general threshold limit value for dust for the alveolar fraction in light of recent studies and classifies such dusts as carcinogenic when these thresholds are exceeded.
Covaris, Inc. introduced the truXTRAC™ High Throughput FFPE DNA Extraction & Purification Kit at the 2014 Advances in Genome Biology and Technology (AGBT) meeting held in Marco Island, Florida.
Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, non-invasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments.
Rather than testing for individual marker genes or proteins, researchers at the University of California, San Diego (UC San Diego) and the Moores UCSD Cancer Center have evidence that groups, or networks, of interactive genes may be more reliable in determining the likelihood that a form of leukemia is fast-moving or slow-growing.
› Verified 7 days ago
| Entity Name | Texas Regional Anesthesia Medical Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457702201 PECOS PAC ID: 8325328628 Enrollment ID: O20161202000581 |
News Archive
The 2011 MAK and BAT Values List compiled by the Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area, a Senate Commission of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), recommends reducing the general threshold limit value for dust for the alveolar fraction in light of recent studies and classifies such dusts as carcinogenic when these thresholds are exceeded.
Covaris, Inc. introduced the truXTRAC™ High Throughput FFPE DNA Extraction & Purification Kit at the 2014 Advances in Genome Biology and Technology (AGBT) meeting held in Marco Island, Florida.
Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, non-invasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments.
Rather than testing for individual marker genes or proteins, researchers at the University of California, San Diego (UC San Diego) and the Moores UCSD Cancer Center have evidence that groups, or networks, of interactive genes may be more reliable in determining the likelihood that a form of leukemia is fast-moving or slow-growing.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Pia Lippincott, MD 250 College Ave, Lancaster, PA 17603-3363 Ph: (717) 291-8271 | Pia Lippincott, MD 1600 Cloister Dr, Lancaster, PA 17601-2390 Ph: (717) 519-0793 |
News Archive
The 2011 MAK and BAT Values List compiled by the Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area, a Senate Commission of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), recommends reducing the general threshold limit value for dust for the alveolar fraction in light of recent studies and classifies such dusts as carcinogenic when these thresholds are exceeded.
Covaris, Inc. introduced the truXTRAC™ High Throughput FFPE DNA Extraction & Purification Kit at the 2014 Advances in Genome Biology and Technology (AGBT) meeting held in Marco Island, Florida.
Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, non-invasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments.
Rather than testing for individual marker genes or proteins, researchers at the University of California, San Diego (UC San Diego) and the Moores UCSD Cancer Center have evidence that groups, or networks, of interactive genes may be more reliable in determining the likelihood that a form of leukemia is fast-moving or slow-growing.
› Verified 7 days ago
Dr. Ashima Arora Vaswani, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 250 College Ave, Lancaster, PA 17603 Phone: 717-358-7349 Fax: 717-291-6734 | |
Casey Joseph Prather, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 250 College Ave Fl 1, Lancaster, PA 17603 Phone: 717-358-7349 Fax: 717-291-6734 | |
Dr. Salvatore J Astarita, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 133 E Frederick St, Lancaster, PA 17602 Phone: 717-394-9821 Fax: 717-394-0175 | |
Dr. Jon B Turula, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 133 E Frederick St, Lancaster, PA 17602 Phone: 717-394-9821 Fax: 717-394-0175 | |
Dr. Margaret A Motl, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 133 E Frederick St, Lancaster, PA 17602 Phone: 717-394-9821 Fax: 717-394-0175 | |
Dr. Robert B Falk Jr., MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 133 E Frederick St, Lancaster, PA 17602 Phone: 717-394-9821 Fax: 717-394-0175 | |
Dr. Kevin F Slenker, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 133 E Frederick St, Lancaster, PA 17602 Phone: 717-394-9821 Fax: 717-394-0175 |